In another example, previous studies have reported that tocilizumab, an anti-IL6R antibody that blocks IL-6 signaling, induced fluctuations in the balance of Treg/Th17 cell subsets in PBMCs from RA patients [13, 14]. The gene discussed is IL6R; the disease is rheumatoid arthritis.